 Kazia Therapeutics Ltds ASX:KZA NASDAQ:KZIA FRA:NV9 chief executive officer and MD James Garner has highlighted the companys progress over the course of the year to date in its March newsletter, stating that the focus remains on preparing a new drug application ND to the US FDA. While he said the oncology-focused biotechnology company had witnessed a critical watershed in its development with the transition of paxalisib into a pivotal study for registration, Kazia was continuing to collect additional data, refining manufacturing and increasing interactions with FDA. 